查詢結果分析
相關文獻
- Impact of KRAS Mutation on Second-line Oxaliplatin-based (FOLFOX-6) Chemotherapy for Metastatic Colorectal Cancer
- Treatment of Ultra-High Risk Gestational Trophoblastic Disease by an EMA/CE Regimen
- Implications of a Failed Prospective Trial of Adjuvant Therapy after Radical Hysterectomy for Stage Ib-IIa Cervical Carcinoma with Pelvic Node Metastases
- 轉移性結腸直腸癌化學治療之新貌
- 轉移性乳癌的化學治療
- 子宮頸癌的預後因素及化學治療在子宮頸癌治療的角色
- 轉移性乳癌化學治療之新利器--微脂體包覆化學藥物Liposomal Doxorubicin
- 小細胞肺癌復發部位之型態分析
- Salvage Chemotherapy Using Mitoxantrone and 5-Fluorouracil Plus Leucovorin for Heavily Pretreated Metastatic Breast Cancer Patients
- Weekly Doxorubicin with Tegafur-Uracil Slowed Progression of Metastatic Hepatocelluar Carcinoma in Schizophrenia Patients
頁籤選單縮合
題 名 | Impact of KRAS Mutation on Second-line Oxaliplatin-based (FOLFOX-6) Chemotherapy for Metastatic Colorectal Cancer=在發生遠端轉移的結直腸癌患者,存有KRAS突變對第二線Oxaliplatin (FOLFOX-6) 的治療影響 |
---|---|
作 者 | 郭益宏; 黃政義; 陳志榕; 徐鴻智; 莊惠絜; 李讚紘; 謝孟樵; 黃文詩; 靳志堅; | 書刊名 | 中華民國大腸直腸外科醫學會雜誌 |
卷 期 | 28:1 2017.03[民106.03] |
頁 次 | 頁34-42 |
分類號 | 416.245 |
關鍵詞 | 轉移; 結直腸癌; 化學治療; Kirsten-ras; Metastases; Colorectal cancer; Chemotherapy; Oxaliplatin; |
語 文 | 英文(English) |
中文摘要 | 目的 探討不同的KRAS 基因表現對第四期結直腸癌病患接受第二線Oxaliplatin 治療的反應與疾病無惡化存活期的差異。方法 於2010 年1 月至2014 年5 月間,共144 位無法進行手術治療的第四期結直腸癌病患於第一線化療後 (FOLFIRI+/-Bevacizumab),因疾病進展接受第二線Oxaliplatin(FOLFOX6) 治療。參與研究的病患追蹤至2014 年12 月,期間分析病患KRAS 突變與野生型在第二線Oxaliplatin 治療下的疾病無惡化存活期。結果 144 位病患中共有59 位病患 (41%) 存在有KRAS (exon 2) 突變;在突變與野生型兩個分群中,原發結直腸惡性腫瘤接受手術切除率 (p = 0.402)、第一線化療,FOLFIRI,併用Bevacizumab 比例 (p = 0.273)、年齡中位數 (60 vs. 61) 及性別 (p = 0.609)、與遠端轉移器官數目 (p = 0.518) 均不存在統計意義的差異。在接受第二線Oxaliplatin 治療下,KRAS 突變分群病患比起野生型分群有較佳的疾病無惡化存活期 (4.8 mo; 95% CI, 3.1 to6.5 mo vs. 3.4 mo; 95% CI, 3.0 to 3.8 mo; p = 0.0048)。在對疾病無惡化存活期進行多變數分析後也顯示出,KRAS 突變對使用oxaliplatin 作為第二線化療,具有較佳反應的預後(hazard ratio, 0.585; 95% CI, 0.399-0.858; p = 0.006)。結論 在這一個觀察研究中發現,無法手術切除的第四期結直腸癌病患接受第二線FOLFOX6 治療時,KRAS 突變的病患可能比野生型病患擁有較長的疾病無惡化存活期。 |
英文摘要 | Purpose. The aim of the present study was to evaluate the correlation between progression-free survival and different Kirsten-ras statuses in second-line oxaliplatin-based treatment. Patients and Methods. From January 2010 to May 2014, 144 patients who had disease progression after treatment with irinotecan and bevacizumab for unresectable metastases or relapses from non-stage IV colorectal cancer were enrolled in this study. All patients received second-line oxaliplatin-based chemotherapy alone and were followed until December 2014. Their progression-free survival rates were compared among Kirsten-ras categories. Results. Of the patients, 59 (41%) had Kirsten-ras mutation of exon 2. We identified several similarities between the wild-type and mutation groups in the distribution of primary cancer resection (p = 0.402), first-line irinotecan- based chemotherapy with bevacizumab (p = 0.273), median age (60 vs. 61), sex (p = 0.609), and numbers of metastatic sites (p = 0.518). The progression-free survival was longer for patients in the mutation group than for those in the wild-type group when they received second-line oxaliplatin (4.8 mo; 95% CI, 3.1 to 6.5 mo vs. 3.4 mo; 95% CI, 3.0 to 3.8 mo; p = 0.0048). In multivariate analysis, Kirsten-ras mutation of exon 2 showed prognostic value regarding progression-free survival during second- line oxaliplatin therapy (hazard ratio, 0.585; 95% CI, 0.399-0.858; p = 0.006). Second-line oxaliplatin-based chemotherapy might cause metastatic colorectal cancer patients with the KRAS mutation of exon 2 to have longer progression-free survival than that of patients with the wild-type Kirsten-ras gene. Conclusions. Second-line oxaliplatin-based chemotherapy prolonged progression- free survival for patients with metastatic colorectal cancer in the Kirsten-rasmutation group compared with those in the wild-type group. Mini Abstract. The study demonstrated differences in the impact of second- line oxaliplatin-based chemotherapy on progression-free survival in patients with different KRAS statuses. In multivariate analysis, KRAS mutation showed independent prognostic value. |
本系統中英文摘要資訊取自各篇刊載內容。